CD8A and neoplasm: We evaluated sequential tumor biopsies during therapy to test the hypotheses that BRAF/MEKi would increase TIL to day 29, with increases in IFNγ signatures and T‐cell homing receptor ligands and expansion of functional intratumoral tumor‐reactive CD8 T‐cells and TIL clonality in the tumor microenvironment.